Findings

What do systematic reviews say?

9 questions · 9 findings · 2 reviews

No studies found 1 · 11.1%GRADE not reported 0 · 0%Very low 0 · 0%Low 6 · 66.7%Moderate 2 · 22.2%High 0 · 0%

The findings closest to your search, judged one by one by TypeSafe's Jev model.

UPDRS III UPDRS scale (motor score). Scale from: 0 to 56. · people with Parkinson's disease

1 finding from 1 review

Creatine for Parkinson's disease 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 194 participants
Low

UPDRS ADL score · people with Parkinson's disease

1 finding from 1 review

Creatine for Parkinson's disease 2014 · Cochrane Headline outcomes only
0.37
2 studies · 194 participants
Low

Change in disability score · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Moderate

Muscle strength · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Low

Acquiring the ability to stand or walk · children with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Change in quality of life · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 38 participants
Low

Change in pulmonary function · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Low

Time from beginning of treatment until death or full‐time ventilation · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Moderate

Adverse events related to treatment · children with SMA types II and III

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Low